Investment
Features
FeesSafety
Academy
More
Pluang+

Compare DexCom, Inc. (DXCM) vs Frontline Plc Ordinary Shares (FRO) Price & Performance

DexCom, Inc.Trade
Frontline Plc Ordinary SharesTrade

Price performance (Past 24H)

Key statistics

DexCom, Inc. vs Frontline Plc Ordinary Shares — how do they compare? DexCom, Inc. trades at $83.97 (market cap $31.86B), while Frontline Plc Ordinary Shares trades at $56.47 (market cap $12.52B). The key difference: DexCom, Inc. is far larger — about 2.5× Frontline Plc Ordinary Shares's market cap, and Frontline Plc Ordinary Shares pays a 9.56% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Frontline Plc Ordinary Shares for 0 Days on average.

DXCMFRO
Market Cap
$31.86B$12.52B
Volume
3,607,0706,375,509
Sector
HealthIndustrials
52-Week High
$92.34$56.26
52-Week Low
$54.84$20.58
Typical Hold Time
62 Days0 Days
Enterprise Value
$31.32B$14.64B
Dividend Yield
—9.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DexCom, Inc.

DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.

The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.

Frontline Plc Ordinary Shares

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DXCM
100% Buy0% Sell
Avg holding period · 62 Days
FRO
77% Buy23% Sell
Avg holding period · 0 Days

About DexCom, Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Read more on DXCM →

About Frontline Plc Ordinary Shares

Frontline operates a fleet of oil tankers that transport crude oil by sea. Its vessels serve global energy trading routes.

Read more on FRO →